A Phase 2a Randomised, Double-Blind, Placebo-Controlled, 2-Period Crossover Study To Assess The Efficacy And Safety Of Mk952 In Patients With Alzheimer's Disease

Trial Profile

A Phase 2a Randomised, Double-Blind, Placebo-Controlled, 2-Period Crossover Study To Assess The Efficacy And Safety Of Mk952 In Patients With Alzheimer's Disease

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs MK 0952 (Primary)
  • Indications Alzheimer's disease; Dementia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 13 May 2016 Status changed from completed to discontinued.
    • 20 Aug 2009 Additional lead trial centres identified as reported by United Kingdom Clinical Research Network record.
    • 04 Mar 2009 New source identified and integrated (1087413 United Kingdom Clinical Research Network)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top